Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5266703
Max Phase: Preclinical
Molecular Formula: C19H17ClN2O
Molecular Weight: 324.81
Associated Items:
ID: ALA5266703
Max Phase: Preclinical
Molecular Formula: C19H17ClN2O
Molecular Weight: 324.81
Associated Items:
Canonical SMILES: CCc1c(-c2ccccc2Cl)cnc(N)c1-c1ccc(O)cc1
Standard InChI: InChI=1S/C19H17ClN2O/c1-2-14-16(15-5-3-4-6-17(15)20)11-22-19(21)18(14)12-7-9-13(23)10-8-12/h3-11,23H,2H2,1H3,(H2,21,22)
Standard InChI Key: ALDNWIGPGPEFQA-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 324.81 | Molecular Weight (Monoisotopic): 324.1029 | AlogP: 4.92 | #Rotatable Bonds: 3 |
Polar Surface Area: 59.14 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.76 | CX Basic pKa: 6.78 | CX LogP: 5.07 | CX LogD: 4.98 |
Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.72 | Np Likeness Score: -0.22 |
1. Li P, Liu HM.. (2020) Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors., 191 [PMID:32092586] [10.1016/j.ejmech.2020.112107] |
Source(1):